The European Commission (EC) has approved marketing authorisation for Switzerland-based Roche's Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) and chemotherapy for initial treatment of people with a specific type of metastatic lung cancer, it was reported yesterday.
The EC has approved the product in combination with Avastin, paclitaxel and carboplatin, for the first-line treatment of adults with metastatic non-squamous non-small cell lung cancer. The Tecentriq combination is only indicated after failure of appropriate targeted therapies in patients with EGFR mutant or ALK-positive non-small cell lung cancer.
The approval was based on data from the phase III IMpower150 study, which indicated that Tecentriq in combination with Avastin and chemotherapy enabled people to live longer compared against Avastin and chemotherapy. IMpower150 is a multicentre, open-label, randomised and controlled phase III study designed to evaluate the efficacy and safety of Tecentriq in combination with chemotherapy (carboplatin and paclitaxel) with or without Avastin in people with stage IV or recurrent metastatic non-squamous non-small cell lung cancer who had not been treated with chemotherapy for their advanced disease. The company hired 1,202 patients in the trial, and randomised to secure Tecentriq plus carboplatin and paclitaxel in the arm A, Tecentriq and Avastin plus carboplatin and paclitaxel in the arm B and Avastin plus carboplatin and paclitaxel Arm C or control arm.
Bioforum, The Data Masters names new President
VolitionRx names new Chief Medical Officer
Quotient Sciences announces new appointments
Syndax Pharmaceuticals names new chief commercial officer
Everest Medicines names new chief medical officer and chief product officer
D3 Bio names new independent board member
Rigel Pharmaceuticals names new executive vice president and chief medical officer
Telix Pharmaceuticals names new group chief operating officer